Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415752 | 0.91 | AURKA (0.51) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2415218 | 0.90 | MAPT (0.49) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2982436 | 0.88 | SMN1; SMN2 (0.59) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2415661 | 0.87 | MAPT (0.49) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2417753 | 0.84 | AURKA (0.60) | AURKAROCK1 | |
| SCHEMBL2418883 | 0.84 | PDE7A (0.49) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2415167 | 0.84 | MAPT (0.50) | MAPTKMT2AALDH1A1AURKAPDE7A | |
| SCHEMBL2418630 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2AALDH1A1AURKA | |
| SCHEMBL2416736 | 0.82 | AURKA (0.52) | MAPTKMT2AALDH1A1KDM4EAURKA | |
| SCHEMBL2418683 | 0.82 | MAPT (0.55) | MAPTMEN1KMT2AALDH1A1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | claimed |
| US-8017643-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-7786048-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-08-31 | — | — | US | disclosed |
| US-20090233813-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-09-17 | — | — | US | disclosed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | CDK2, MAP3K19, MAP3K15 | MAPT 2293/4885MEN1 2694/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.